logo
Menu
Innovation Observatory > Reports > Drugs > Axitinib for Patients at High Risk of Recurrence of Renal Cell Carcinoma – Adjuvant

< Back

Axitinib for Patients at High Risk of Recurrence of Renal Cell Carcinoma – Adjuvant

Drugs

Cancer and Palliative Care

March 2018


Renal cell carcinoma (RCC) is the most common type of kidney cancer. RCC affects the lining of tiny tubes within the kidney which filter waste from the blood, making urine. Symptoms include blood in urine, feeling of lump or mass in the kidney area, weight loss, raised temperature and sweating, back pain on one side (below the ribs), tiredness, loss of appetite and a general feeling of poor health. The main treatment for RCC is surgery to remove the cancer by partly or totally removing the kidney. Some patients are at high risk of their cancer returning after surgery, especially those who have large tumours which may not be possible to totally remove.
Axitinib is a tablet taken twice per day which works by interfering with the growth of the blood vessels which supply blood to the cancer cells. In other types of cancer, Axitinib has been seen to slow down the growth and stop cancers from spreading to other parts of the body. Axitinib is already available to treat RCC which has already advanced or spread, however if axitinib is licenced for use after surgery to prevent the growth and spread of further tumours (as an adjuvant therapy), this may prevent the progression and spread of RCC to other sites of the body.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts
Get Alerts